C.R. Bard, Inc. (NYSE:BCR)

CAPS Rating: 4 out of 5

The Company is engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices.

Results 21 - 29 of 29 : « Previous 1 2

Recs

0
Member Avatar akbm7195 (57.36) Submitted: 7/15/2008 8:15:39 PM : Outperform Start Price: $86.19 BCR Score: +3.94

Healthcare leader.

Recs

0
Member Avatar oinochoe (54.16) Submitted: 4/25/2008 10:09:35 PM : Outperform Start Price: $90.52 BCR Score: +12.38

A long term hold. This one is a buy and keep with its growing revenue year after year and its dividend payments.

Recs

1
Member Avatar jwj8741 (73.38) Submitted: 4/24/2008 9:47:39 AM : Outperform Start Price: $88.85 BCR Score: +12.84

Bard has come out with several upgrades and new technologies pertaining to infection control solutions. Bard is already well known in the medical industry as a proven supplier of quality medical urology equipment. The added upgrades and equipment that Bard is coming out with is sure to raise their stock 5 to 8 percent in the coming months.

Recs

0
Member Avatar medviceguy (86.91) Submitted: 3/24/2008 6:17:12 PM : Outperform Start Price: $95.57 BCR Score: +2.94

Growing consistently in a recession proof industry

Recs

0
Member Avatar Ernbo6 (57.95) Submitted: 10/10/2007 1:51:49 PM : Outperform Start Price: $84.55 BCR Score: +29.16

C. R. Bard, Inc. (Bard) is engaged in the designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells a range of products worldwide to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities. In general, the Company�s products are intended to be used once and then discarded or implanted either temporarily or permanently. Bard has four major product group categories: vascular, urology, oncology and surgical specialties. It also has a product group of other products. During the year ended December 31, 2006, it acquired Venetec International, Inc. and its StatLock line of catheter stabilization products. In 2006, Bard introduced its line of natural tissue hernia products including the Collamend and Allomax patches to repair complex ventral hernias.

Recs

0
Member Avatar onefreshone (66.28) Submitted: 8/12/2007 1:24:44 PM : Outperform Start Price: $78.50 BCR Score: +32.33

Long and Short term. Baby boomer stock.

Recs

1
Member Avatar JakeSpider (95.02) Submitted: 1/14/2007 2:02:07 AM : Outperform Start Price: $79.19 BCR Score: +28.16

A good stock for people who like to get rich slowly but steadily!

Recs

0
Member Avatar aubailey (< 20) Submitted: 12/6/2006 11:59:16 AM : Outperform Start Price: $79.87 BCR Score: +26.20

Steady medical device manufacturer that turns out 14% sales and 10% income regularly.

Recs

4
Member Avatar oncqueen (69.98) Submitted: 9/24/2006 6:15:37 PM : Outperform Start Price: $72.14 BCR Score: +32.04

60% of the market share for implantable ports for chemotherapy. Their new Powerport is capable of withstanding the pressure of injections for CT scans and other imaging studies. Let's see, how many chemo patients whose veins are shot and will need CT scans (and others) frequently, will insist on the only port designed to withstand those pressures, rather than saying, "Oh, that's OK, dig around 4 or 5 times until you find a vein."? This will corner that particular market.

Results 21 - 29 of 29 : « Previous 1 2

Featured Broker Partners


Advertisement